Literature DB >> 9704015

The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding.

J M Mariner1, J B McMahon, B R O'Keefe, K Nagashima, M R Boyd.   

Abstract

Concentrations of the potent, HIV(human immunodeficiency virus) inactivating protein, cyanovirin-N (CV-N), which completely inhibit HIV-1 infectivity, do not block the binding of soluble CD4-receptor (sCD4) to HIV-1 lysates nor the attachment of intact HIV-1 virions to several target T-cell lines. Furthermore, in contrast to the known disassociative effects of sCD4 on viral envelope glycoproteins, treatment of HIVRF with high concentrations of CV-N results in complete viral inactivation but without apparent shedding of gp120 or other ultrastructural changes. These results are consistent with the view that the virucidal effects of CV-N result from interference with step(s) in the fusion process subsequent to the initial binding of the virus to target cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9704015     DOI: 10.1006/bbrc.1998.9060

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Non-Antiretroviral Microbicides for HIV Prevention.

Authors:  Yanille Scott; Charlene S Dezzutti
Journal:  AIDS Rev       Date:  2016 Jul-Sep       Impact factor: 2.500

2.  Enrichment of distinct microfilament-associated and GTP-binding-proteins in membrane/microvilli fractions from lymphoid cells.

Authors:  Jian-Jiang Hao; Guanghui Wang; Trairak Pisitkun; Genaro Patino-Lopez; Kunio Nagashima; Mark A Knepper; Rong-Fong Shen; Stephen Shaw
Journal:  J Proteome Res       Date:  2008-05-28       Impact factor: 4.466

3.  Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.

Authors:  B Dey; D L Lerner; P Lusso; M R Boyd; J H Elder; E A Berger
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.

Authors:  M T Esser; T Mori; I Mondor; Q J Sattentau; B Dey; E A Berger; M R Boyd; J D Lifson
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope.

Authors:  Yossef Raviv; Mathias Viard; Julian W Bess; Elena Chertova; Robert Blumenthal
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.

Authors:  T Mori; M R Boyd
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  Characterization of the effects of aryl-azido compounds and UVA irradiation on the viral proteins and infectivity of human immunodeficiency virus type 1.

Authors:  Julie M Belanger; Yossef Raviv; Mathias Viard; Michael Jason de la Cruz; Kunio Nagashima; Robert Blumenthal
Journal:  Photochem Photobiol       Date:  2010 Sep-Oct       Impact factor: 3.421

8.  Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry.

Authors:  Bushra Yasin; Wei Wang; Mabel Pang; Natalia Cheshenko; Teresa Hong; Alan J Waring; Betsy C Herold; Elizabeth A Wagar; Robert I Lehrer
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  Hornerin, an S100 family protein, is functional in breast cells and aberrantly expressed in breast cancer.

Authors:  Jodie M Fleming; Erika Ginsburg; Shannon D Oliver; Paul Goldsmith; Barbara K Vonderhaar
Journal:  BMC Cancer       Date:  2012-06-22       Impact factor: 4.430

10.  Development of an HIV-1 Microbicide Based on Caulobacter crescentus: Blocking Infection by High-Density Display of Virus Entry Inhibitors.

Authors:  Christina Farr; John F Nomellini; Evan Ailon; Iryna Shanina; Sassan Sangsari; Lisa A Cavacini; John Smit; Marc S Horwitz
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.